Reading LC-MS Peptide Identity: Exact Mass, Isotope Envelopes and MS/MS

Mass spectrometry can provide powerful peptide identity evidence, but the sentence “mass matches” is incomplete. A useful interpretation asks which ion was measured, how charge states were assigned, whether the neutral mass was deconvoluted correctly, what mass tolerance was used and whether fragment evidence supports the proposed sequence.

ICH Q6B describes mass spectrometry and peptide mapping as complementary characterization tools. FDA’s synthetic-peptide guidance also emphasizes control of peptide-related impurities. The practical lesson is that identity is stronger when orthogonal observations converge, not when a single rounded molecular-weight value is copied into a certificate.

Why a peptide appears at several m/z values

Electrospray ionization commonly produces multiple charge states. The instrument measures mass-to-charge ratio, written m/z, rather than neutral molecular mass directly. A peptide carrying three protons appears at a different m/z than the same molecule carrying four. Software can combine the charge-state envelope into a deconvoluted mass, but the underlying spectrum and charge assignment should remain reviewable.

Adducts, counterions, oxidation, dehydration or other modifications can shift observed ions. The expected ion formula must be stated: average or monoisotopic mass, neutral molecule or protonated ion, and whether terminal modifications are included.

Exact mass narrows the possibilities; it does not prove the order

A high-resolution intact-mass match can rule out many wrong compositions. It still cannot necessarily distinguish leucine from isoleucine, positional isomers or two sequences with the same elemental composition. A sequence permutation can share an intact mass. That is why a mass match supports identity but should not be described as complete sequence confirmation on its own.

What MS/MS adds

Tandem MS isolates a precursor and fragments it. A series of product ions can support residue order across parts of the sequence and localize certain modifications. Review should report sequence coverage, mass error and ambiguous regions rather than simply mark “pass.” High coverage is not identical to complete structural proof, and some residues or labile modifications require other methods.

For difficult sequences, complementary fragmentation, peptide mapping, amino-acid analysis or another orthogonal technique may be appropriate. The method set should follow the identity risk and specification, not a fixed marketing checklist.

How to inspect a lot-specific LC-MS record

1. Match the sample name and lot to the COA and acquisition record.
2. Identify instrument mode, ionization, mass range and resolution.
3. Confirm whether the reported value is monoisotopic or average and which ion formula was calculated.
4. Review the raw charge-state envelope, not only a deconvoluted screenshot.
5. Check the numerical observed mass, theoretical mass, absolute or ppm error and acceptance criterion.
6. If sequence confirmation is claimed, inspect fragment assignments, coverage and unresolved ambiguities.
7. Use chromatographic context to determine whether additional components or co-elution were observed.

Identity evidence is not purity or content

A convincing spectrum can be obtained from a minor component in a mixed sample. Conversely, a dominant HPLC peak does not identify itself. Quantitative content requires a suitable assay; chromatographic purity requires a defined separation and integration method. These records should agree while retaining their separate meanings.

The strongest short claim is specific: “The batch record reports an observed intact mass of X under method Y, within criterion Z, with the attached spectrum.” Without those lot-specific elements, a general LC-MS explainer can teach interpretation but cannot certify a product.

Editorial source check: NHD evidence editorial workflow · 2026-08-28